WO2012094574A3 - Nanoparticules de polyribonucléotide stabilisées - Google Patents

Nanoparticules de polyribonucléotide stabilisées Download PDF

Info

Publication number
WO2012094574A3
WO2012094574A3 PCT/US2012/020445 US2012020445W WO2012094574A3 WO 2012094574 A3 WO2012094574 A3 WO 2012094574A3 US 2012020445 W US2012020445 W US 2012020445W WO 2012094574 A3 WO2012094574 A3 WO 2012094574A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
polymeric nanoparticles
stabilized polymeric
stabilized
polyribonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/020445
Other languages
English (en)
Other versions
WO2012094574A2 (fr
Inventor
Hai-Quan Mao
Masataka Nakanishi
Rajesh Patil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of WO2012094574A2 publication Critical patent/WO2012094574A2/fr
Publication of WO2012094574A3 publication Critical patent/WO2012094574A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une ou plusieurs nanoparticules de polymère stabilisées comprenant : (a) des polymères polycationiques, (b) au moins une ou plusieurs molécules de polyribonucléotide, et (c) un réactif de stabilisation anionique. Les nanoparticules de polymère stabilisées présentent une uniformité élevée avec une petite taille, et présentent une stabilité augmentée vis-à-vis d'une force ionique physiologique et d'un milieu contenant du sérum. L'efficacité de transfection et de silençage génique des nanoparticules de polymère stabilisées est nettement améliorée par rapport aux nanoparticules qui ne contiennent pas le réactif de stabilisation dans du milieu contenant du sérum. La présente invention concerne en outre des procédés de fabrication des nanoparticules de polymère stabilisées, des compositions pharmaceutiques comprenant celles-ci, et des procédés pour leur utilisation.
PCT/US2012/020445 2011-01-06 2012-01-06 Nanoparticules de polyribonucléotide stabilisées Ceased WO2012094574A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161430242P 2011-01-06 2011-01-06
US61/430,242 2011-01-06

Publications (2)

Publication Number Publication Date
WO2012094574A2 WO2012094574A2 (fr) 2012-07-12
WO2012094574A3 true WO2012094574A3 (fr) 2012-11-01

Family

ID=46457978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/020445 Ceased WO2012094574A2 (fr) 2011-01-06 2012-01-06 Nanoparticules de polyribonucléotide stabilisées

Country Status (1)

Country Link
WO (1) WO2012094574A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015179492A1 (fr) * 2014-05-20 2015-11-26 The Johns Hopkins University Nanoparticules d'acides nucléiques à forme contrôlée pour une administration in vivo d'agents thérapeutiques à base d'acides nucléiques
EP3283059B1 (fr) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Procédé de production de compositions d'arn
WO2018041921A1 (fr) 2016-08-31 2018-03-08 Curevac Ag Dispositif de mélange pour la production d'une composition d'acide nucléique liquide
CN110964816A (zh) * 2019-11-20 2020-04-07 深圳市鲲鹏未来科技有限公司 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法
CN113181421B (zh) * 2021-05-12 2022-11-15 广州贝奥吉因生物科技股份有限公司 一种具有抗菌和免疫调节功能的水凝胶伤口敷料及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226528A1 (en) * 2007-10-29 2009-09-10 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
WO2009133968A1 (fr) * 2008-04-30 2009-11-05 国立大学法人東京大学 Polyplex ternaire à conversion de charge
US20100015232A1 (en) * 2006-07-07 2010-01-21 Aarhus Universitet Nanoparticles for nucleic acid delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015232A1 (en) * 2006-07-07 2010-01-21 Aarhus Universitet Nanoparticles for nucleic acid delivery
US20090226528A1 (en) * 2007-10-29 2009-09-10 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
WO2009133968A1 (fr) * 2008-04-30 2009-11-05 国立大学法人東京大学 Polyplex ternaire à conversion de charge

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US9089604B2 (en) 2012-04-02 2015-07-28 Moderna Therapeutics, Inc. Modified polynucleotides for treating galactosylceramidase protein deficiency
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins

Also Published As

Publication number Publication date
WO2012094574A2 (fr) 2012-07-12

Similar Documents

Publication Publication Date Title
Akram et al. Interval-valued fuzzy graphs
AU2017277731A1 (en) Hybrid carriers for Nucleic Acid cargo
EP3049116A4 (fr) Administration de gènes médiée par des nanoparticules, édition génomique et modification ciblée par un ligand dans diverses populations de cellules
EA201600044A1 (ru) Композиции для интродукции рнк в клетки
WO2013173789A3 (fr) Compositions d'oligonucléotide antisens
SG195194A1 (en) Nanogels
CA2912615C (fr) Structure de preambule a haute efficacite pour reseau local sans fil
PH12013500513A1 (en) Nanocapsules containing microemulsions
WO2011130694A3 (fr) Polymères de haut poids moléculaire contenant des zwitterions
WO2014201015A8 (fr) Méthodes et compositions pour la modification d'adn cible
MX364396B (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
WO2012024526A3 (fr) Conjugués, particules, compositions et procédés associés
WO2010057150A8 (fr) Lipides-polymères libérables pour systèmes de délivrance d'acides nucléiques
WO2010033822A3 (fr) Stratégies thérapeutiques et diagnostiques
WO2008042973A3 (fr) Formulations contenant un lipide
MX2010003323A (es) Composiciones de poliplex de quitosana-acido nucleico de alta concentracion.
MY165507A (en) Synthetic mimics of mir-34
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
HK1212381A1 (en) Mirna modulators of chronic visceral inflammation
MX353705B (es) Nanoparticulas de quitosana derivadas dualmente y metodos de fabricacion y uso de las mismas para transferencia genetica in vivo.
EP2540764A3 (fr) Composition de poly(organophosphazène) pour biomatériaux
WO2012106536A3 (fr) Systèmes, ensembles pointes, procédés et trousses pour l'introduction de matière à l'intérieur de cellules
MX2014004476A (es) Composicion hemostatica.
AU2012305327B2 (en) Polymer-type fluorescent molecule probe
WO2010145849A3 (fr) Systèmes de délivrance de médicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12732127

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12732127

Country of ref document: EP

Kind code of ref document: A2